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In the past decade, our increased elucidation of the molecu-
lar basis of cancer has led to the development of novel tar-
geted strategies for specifi c inhibition of cancer signaling 
pathways that control growth, proliferation, apoptosis, and an-
giogenesis. Several monoclonal-antibody-based therapeutics 
and small-molecule drugs have received clearance for use as 
human therapeutics [1]. However, among these successes are 
many candidate drugs that have failed in clinical trials despite 
promising preclinical results [2].
The development of targeted therapeutics is expensive and 
time consuming. In their Critical Path Initiative, the United 
States Food and Drug Administration emphasized the need for 
more effective tools to facilitate the rapid development of im-
proved cancer therapeutics. One such tool is the use of tar-
geted molecular optical imaging probes or contrast agents to 
visualize the underlying processes in cancer.
Optical imaging, also known as molecular imaging, is a 
rapidly developing fi eld of research aimed at noninvasively 
interrogating animals for disease progression, evaluating the 
effects of a drug, assessing the pharmacokinetic behavior of 
a drug, or identifying molecular biomarkers of disease. A pre-
requisite of molecular imaging is the development of spe-
cifi c, targeted imaging contrast agents to assess these biolog-
ical processes. Several optical aids have shown great utility 
in animal studies, including bioluminescence, fl uorescent pro-
teins, and fl uorochrome-labeled agents. However, only the lat-
ter have the advantage of being potentially relevant to human 
clinical applications.
The complexity of developing robust fl uorochrome-la-
beled optical agents is often underestimated. Many studies de-
scribe the use of these agents, but guidelines for their devel-
opment and testing are not readily available. The purpose of 
this review is to outline some of the considerations for devel-
oping and using fl uorochrome-labeled optical contrast agents 
in animals. For simplicity, we have focused on the use of or-
ganic fl uorochromes as labeling agents. These types of probes 
are generally the most straightforward to develop and have 
the greatest potential for translation to human clinical use. 
Nanoparticles such as quantum dots, while useful for some 
animal studies, are hampered by clearance issues and toxicity 
and will not be specifi cally discussed. However, the principles 
described here are generally applicable to any fl uorescent op-
tical imaging agent.
Principles of fl uorescence imaging
The use of fl uorochrome-labeled optical agents such as la-
beled antibodies, receptor-binding ligands, small mol-
ecules, peptides, and activatable probes offers a fl exi-
ble and direct imaging methodology. The fl uorescent labels 
can be visualized by excitation with an appropriate light 
source and capture of the emitted photons with a charge-
coupled device camera or other optical detector. Sev-
eral commercially available imaging systems enable visu-
alization of these probes in mice. These include systems 
from LI-COR Biosciences (http://www.licor.com/), CRI 
(http://www.cri-inc.com/), Kodak (http://www.kodak.com/), 
and Xenogen (http://www.xenogen.com/).
In fl uorescent imaging, there are generally three parame-
ters used to characterize the interaction of photons with tis-
sues: light absorption, light scattering, and fl uorescent emis-
sion. One of the most important considerations in optical 
imaging is maximizing the depth of tissue penetration. Ab-
sorption and scattering of light are largely a function of the 
wavelength of the excitation source [3]. Light is absorbed by 
endogenous chromophores found in living tissue, including 
hemoglobin, melanin, and lipid [3], [4], [5], [6], and [7]. In 
general, light absorption and scattering decrease with increas-
ing wavelength. Below ~700 nm, these effects result in shal-
low penetration depths of only a few millimeters [3]. Thus, in 
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the visible region of the spectrum, only superfi cial assessment 
of tissue features is possible. Above 900 nm, water absorption 
can interfere with signal-to-background ratio. Because the ab-
sorption coeffi cient of tissue is considerably lower in the near 
infrared (NIR) region (700–900 nm), light can penetrate more 
deeply, to depths of several centimeters [3], [4], [5] and [6]. 
Fluorochromes with emissions in the NIR are not hindered by 
interfering autofl uorescence, so they tend to yield the highest 
signal-to-background. The combination of increased depth of 
penetration and reduced autofl uorescence makes NIR fl uoro-
chromes ideally suitable for optical imaging in small animals 
and potentially in humans also (Figure 1). 
Near infrared fl uorochromes
A key to enabling optical imaging has been the development 
of suitable NIR fl uorochromes. Important criteria for effective 
optical imaging fl uorochromes include excitation and emis-
sion maxima in the NIR between 700 and 900 nm, high quan-
tum yield [3], [4], [5], [6] and [7], chemical and optical stabil-
ity, and suitable pharmacological properties including aqueous 
solubility, low nonspecifi c binding, rapid clearance of the free 
dye, and low toxicity. The dyes most commonly used for fl uo-
rescent optical imaging are listed in Table 1. 
The cyanine dye Cy5.5 has been used frequently for in vivo 
imaging. The excitation/emission maxima (675 nm/695 nm) 
are close to the NIR region, yielding acceptable signal-to-
background. Other dyes with excitation and emission maxima 
in this region include IRDye 700DX, IRDye 680, Alexa Fluor 
700, and Alexa Fluor 680. Although excitation and emission 
wavelengths of these dyes are maximal in the more favor-
able red region, they do not give the optimal performance that 
can be achieved by moving farther into the NIR. Thus they 
are best used in situations when the highest sensitivity is not
required. However, the pthalocyanine dye IRDye 700DX has 
properties that may make it attractive for imaging. IRDye 
700DX is considerably less sensitive to photobleaching than 
many organic fl uorochromes; Peng et al. [8] have shown that 
IRDye700DX is 100 times more photostable than Alexa Fluor 
680 and Cy5.5. In addition, members of the pthalocyanine dye 
class have been used for photodynamic therapy in the treat-
ment of several types of cancer[9]. The photodynamic char-
acteristics relevant to tumor therapy require prolonged expo-
sure to the light source and therefore would not interfere with 
tumor biology during the short exposures used for imaging. 
Therefore, pthalocyanines have the potential to serve not only 
as imaging agents but also as therapeutics.
The most widely used dyes with true NIR character in-
clude IRDye 800CW, Cy7, and Alexa Fluor 750. The excita-
tion/emission ranges for these dyes are shown schematically 
in Figure 1. In particular, IRDye 800CW has excitation/emis-
sion maxima of 774 nm/789 nm, which are centered at the 
optimal wavelength for in vivo imaging. This dye has been 
shown to be superior in performance to Cy5.5 with regard to 
signal-to-background [10].
Targets and ligands
Many targeted optical probes have been described in the liter-
ature. Targets include cell surface receptors, metabolic path-
ways, hormone receptors, apoptotic markers, and enzymatic 
activities [11]. High-affi nity probes may be developed by ra-
tional investigation, combinatorial chemical synthesis, or 
phage display. An effective agent reaches the target at a suf-
fi cient concentration and/or is retained there for a suffi cient 
length of time to be visible at the time of imaging. Obstacles 
such as rapid excretion, metabolism, nonspecifi c binding, and 
physical barriers to the agent reaching the target must be over-
come for a targeted optical agent to function robustly.
Delivery barriers present the greatest obstacle but can be 
circumvented. One approach is to take advantage of normal 
cellular transport and endocytic processes by targeting surface 
receptors or transport pathways that internalize the optical 
agent. Growth factor receptors are an example in which the 
binding of a fl uorochrome-labeled agent stimulates internal-
Figure 1. Schematic representation of the region of optimal sig-
nal-to-background ratio in tissue. Hemoglobin can interfere below 
700 nm while water interferes above 900 nm. The excitation and 
emission regions for several dyes commonly used in optical imaging 
are also indicated. 
Table 1. 
Excitation and emission maxima of fl uorescent dyes commonly used 
for optical imaging
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ization via endocytosis. This has the added benefi t of ampli-
fying the fl uorescent signal, since the fl uorochrome will accu-
mulate in the target cells. A second approach is to incorporate 
a peptide membrane translocation signal into the optical agent 
such that active transport of the imaging agent across the cell 
membrane results. Signal peptides such as the HIV tat peptide 
have been successfully used to transport nanoparticles into 
cells [12].
Nonspecifi c binding is another critical issue for nonin-
vasive tumor imaging. In vivo, the inability to eliminate un-
bound ligand can cause low signal-to-background. In addi-
tion, nonspecifi c binding or retention of the optical probe will 
yield false positive results. Careful assessment of the optical 
agent clearance pattern and verifi cation of specifi c signals by 
competition experiments can address this issue.
Antibody conjugates
Many of the fi rst fl uorochrome-conjugated targeted imag-
ing agents were antibodies. For example, indocyanine-con-
jugated monoclonal antibodies against cells derived from a 
squamous cell carcinoma have been used to image A431 cell 
xenografts in nude mice [13]. Detection of the xenografts 
was sensitive and specifi c. Cy3-, Cy5-, and Cy5.5-conju-
gated monoclonal antibodies have been used to direct SSEA-
1 for detection of MH-15 teratocarcinoma xenografts [14]. In 
this study, fl uorescence did concentrate in the tumor, but sig-
nifi cant background from the conjugate was observed in the 
kidneys and bladder. The NIR dye, Cy5.5, appeared to yield 
the best signal-to-background. Finally, minibodies directed 
against the extra-domain B of fi bronectin and conjugated to 
Cy7 have been used to successfully image atherosclerotic 
plaques in a mouse model [15].
Although antibody conjugates have been successfully 
used, they have several undesirable features, primarily due to 
the size of the antibody. Larger molecules, such as antibod-
ies, can elicit an adverse immune response from the host ani-
mal, and their long half-life in the blood results in high back-
ground fl uorescence and long clearance times [16] and [17]. 
In addition, large biomolecules are often taken up preferen-
tially by the liver, precluding imaging of liver-proximal or-
gans [18]. Finally, for the contrast agent to effectively pene-
trate to the target site, it must diffuse from the vasculature to 
the site of the pathology; larger molecules show very poor dif-
fusion characteristics which may prevent them from reaching 
the target site [19].
Tumor surface proteins
Tumor surface proteins offer diverse possibilities for targeting 
of optical probes. An excellent example is a receptor-binding 
ligand. Growth factors are a popular choice for optical imag-
ing agents because, in addition to high-affi nity targeting, the 
ligand and its fl uorescent label are often internalized by the 
normal endocytic pathway, amplifying the signal in the tumor 
cells. Fluorochrome-labeled epidermal growth factor (EGF) 
has been a versatile tumor imaging agent because the epider-
mal growth factor receptor (EGFR) is overexpressed on the 
surface of many types of tumor cells [20], [21], [22], [23], and 
[24]. In a study measuring the diffusion of small molecules 
across the extracellular space in rat brains, Thorne et al. [25] 
showed that EGF labeled with Oregon green 514 could be 
used as a reporter. Ke et al. [26] used Cy5.5-labeled EGF to 
target human breast tumor cells implanted in mice. The EGF-
Cy5.5 accumulated specifi cally in the tumors and uptake was 
blocked by pretreatment of animals with C225 anti-EGFR 
monoclonal antibody (cetuximab).
Similarly, we have demonstrated the utility of EGF labeled 
with IRDye 800CW for analysis of orthotopic prostate tumors 
in mice [27] and [28]. IRDye 800CW EGF accumulated spe-
cifi cally in the tumors, and metastatic spread of the primary 
orthotopic tumor to the paraaortic lymph nodes was detected. 
EGF is known to stimulate tumor growth, and this is an impor-
tant concern for its use as an imaging agent. Comparison of tu-
mors excised from animals injected with labeled EGF only at 
the study endpoint to tumors excised from mice that had been 
injected at weekly intervals over a 6 week period demonstrated 
no stimulation of tumor growth by the fl uorochrome-conju-
gated ligand used in this longitudinal study [27].
Endostatin, a 20-kDa fragment of collagen XVIII, is a po-
tent inhibitor of angiogenesis. Using Cy5.5-labeled endostatin, 
Citrin et al. [29] were able to demonstrate that the labeled op-
tical agent bound specifi cally to tumor xenografts in C57BL 
mice, suggesting that the antiangiogenic effect of endostatin 
is due to its action directly on the tumor cells rather than to 
a general antiangiogenic effect. The Cy5.5-endostatin bound 
specifi cally to the tumor and the signal persisted for up to 7 
days postintraperitoneal injection [29].
Apoptosis plays an important role in a number of disease 
pathologies, particularly cancer. One of the earliest markers 
of apoptosis is the externalization of phosphatidylserine. An-
nexin V, a 36-kDa protein, exhibits high affi nity for phosphati-
dylserine and has been used to detect apoptosis in vivo. Petro-
vsky et al. [30] and Ntziachristos et al. [31] demonstrated the 
utility of Cy5.5-labeled annexin V for detection of apoptosis 
in a mouse tumor model. This marker may be useful in study-
ing the antiproliferative effects of chemotherapeutic agents on 
a variety of cancers.
Somatostatin receptors and their ligands have been used 
as a targeting system for tumor imaging and radiotherapy of 
cancer for over 15 years. Radiolabeled synthetic analogues of 
somatostatin have been used to successfully image gastric or 
pancreatic tumors and small-cell lung cancer (SCLC) [32] and 
[33]. SCLC is a major cause of death in western countries. 
The substitution of fl uorochrome-tagged somatostatin and 
several analogues has enabled imaging of human H69 SCLC 
tumor xenografts in mice using fi ber-optic spectrofl uorimetry. 
Thus, near-infrared-conjugated peptides may have signifi cant 
clinical impact on tumor detection by endoscopy, mammogra-
phy, and intraoperative imaging.
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Peptides and small molecules
Because of their small size, convenience of handling, and at-
tractive pharmacokinetic properties, peptides are useful agents 
for in vivo imaging. Peptides targeting integrins, a family of 
cell surface receptors that broadly regulate tumor growth, me-
tastasis, and angiogenesis, have been successful agents for im-
aging neovascular density [34], [35], [36], [37], [38], [39], 
[40], and [41]. Chen et al. [37] and Achilefu et al. [41] used an 
NIR peptide conjugate, arginine-glycine-aspartic acid (RGD), 
targeting αvβ3 integrin, to detect and image tumor xenografts 
and to monitor angiogenesis. Tumor uptake of the Cy5.5 RGD 
peptide was specifi c and could be blocked by preinjection 
with unlabeled RGD. Houston et al. [42] used an RGD peptide 
doubly labeled with 111indium and IRDye 800CW to directly 
compare NIR optical imaging with scintigraphy. The authors 
found the signal-to-background ratio signifi cantly higher for 
IRDye 800CW than for the radioactive label.
In general, small molecules and peptide imaging agents 
clear the system quickly, translating to a reduction in fl uo-
rescent background when imaging. In all cases described 
above, the agents cleared through the kidneys without pool-
ing in the liver. The small size also greatly reduces the possi-
bility of an adverse immune response. Finally, fl uorochrome-
labeled small molecules and peptides penetrate to the target 
effi ciently because of their increased ability to diffuse from 
the vasculature.
Activatable probes
The last category of fl uorescent agents, activatable probes 
or “molecular beacons” [43] and [44], specifi cally yield a 
fl uorescent signal only when activated by an enzyme tar-
get. Most activatable probes are protease substrates. Prote-
ase levels are elevated in the extracellular space of many tu-
mors, where they play roles in invasion and metastasis [45], 
[46], [47], [48], and [49] and present a physically accessi-
ble target. Typically, these probes contain multiple NIR fl uo-
rochromes coupled to peptide sequences that can be cleaved 
by the protease. The proximity of the fl uorochromes to each 
other results in quenching that is relieved upon cleavage by 
the target protease to generate a fl uorescent signal. Use of 
fl uorochrome/quencher pairs separated by the peptide target 
sequence has also been reported.
Proteases that have been targeted by activatable probes in-
clude cathepsins, matrix metalloproteinases (MMPs), pros-
tate-specifi c antigen, thrombin, caspase-3, and interleukin-1β 
converting enzyme [50]. An example of the signal sensitivity 
that can be achieved using these agents is the visualization of 
MMP-2 activity [50], [51], and [52]. In vitro, the authors ob-
served an 850% increase in NIR fl uorescence intensity when 
the probe was cleaved and specifi c activation could be blocked 
by MMP-2 inhibitors. MMP-2-positive human fi brosarco-
mas were visualized and differentiated from MMP-2-negative 
mammary adenocarcinomas using this probe.
Developing an optical imaging agent
Below, we will discuss some of the critical parameters in-
volved in developing, validating, and using an optical im-
aging agent. We present an overview of the process as it 
applies to tumor imaging, using as an example the IRDye 
800CW EGF imaging agent that we recently developed [27] 
and [28]. Again, although we use this agent as an example, 
the principles described will be applicable to any dye-conju-
gate optical agent.
Conjugating probes with NIR dyes
Development of an optical targeting agent begins with co-
valent attachment of an NIR dye to the targeting compound. 
Many dyes are available with an N-hydroxysuccinimidyl 
(NHS) ester, which is activated for simple one-step coupling 
to free amines. NHS esterifi ed NIR dyes may be purchased in 
bulk or in prepackaged labeling kits. Methods for removal of 
unreacted dye may include HPLC, FPLC, or dialysis. Purifi -
cation will be dictated by the molecular weight and chemical 
properties of the conjugates.
For in vivo imaging applications, the dye/protein ratio of 
the conjugate may affect biological or biochemical activity of 
the protein, signal-to-background ratio, clearance, and biodis-
tribution [52]. The optimal ratio of coupling is unique to each 
targeting agent. For example, Ntziachristos et al. [31] found 
that annexin V labeled with Cy5.5 at a dye/protein ratio of 1 
retained its ability to bind phosphatidylserine on the surface of 
cells induced for apoptosis, while the same molecule labeled 
at a dye/protein ratio of 2.4 had lost its binding capability.
If the optical imaging agent is based on a commercially 
available reagent such as an antibody or receptor ligand, dif-
ferences in preparation and purifi cation may impact perfor-
mance. We conjugated IRDye 800CW to human recombinant 
EGF from fi ve different commercial sources, at equivalent 
dye/protein ratios, and evaluated relative signal intensity by 
In-Cell Western (ICW) [28]. As shown in Figure 2, there were 
considerable differences in the amounts of EGF bound to the 
cells. Variations in signal strength measured in this fashion 
have the potential to predict probe performance in vivo as we 
have demonstrated [28]. 
Testing the performance and specifi city of an optical im-
aging agent in vitro
Validation of targeting agent effi cacy and specifi city in vitro 
is an important prelude to animal studies. Specifi city can be 
demonstrated on cells in culture or in suspension by block-
ing the target with an antibody or by competition with the un-
labeled agent. In targeting somatostatin receptors, Becker et 
al. [53] used a fl ow cytometric assay to quantify binding of 
the agent. As mentioned above, Ntziachristos et al. [31] used 
whole-cell competition assays to demonstrate both probe spec-
ifi city and binding affi nity. Another group used a radioactive 
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displacement assay [54]. 125I-labeled echistatin, an integrin-
binding ligand, was added to integrin-expressing cell cultures 
and allowed to bind. The degree of displacement of the radio-
active echistatin by Cy7-labeled RGD peptide was used as a 
measure of specifi city and binding affi nity.
We have used the ICW or cytoblot to evaluate IRDye 
800CW EGF for binding and specifi city prior to actual test-
ing in mice [27] and [55]. In this assay, PC3M-LN4 and 
22Rv1 human prostate adenocarcinoma cells were cultured 
in microtiter plates and treated with serial dilutions of la-
beled EGF (Figure 3A) to verify high affi nity binding of 
EGFR-targeted dye relative to the low binding of free dye 
alone (Figure 3B). Specifi city was then established in two 
ways: by blocking access of EGF to its receptor with the 
anti-EGFR monoclonal antibody C225 (also known as ce-
tuximab or Erbitux, Figure 3C) and by competition with un-
labeled EGF (Figure 3D). Fluorescence of the microplate 
was quantifi ed by NIR imaging, and a DNA stain was used 
to normalize variations in cell number. 
Characterization of the targeting agent in a cell-based as-
say can simplify probe development. While success in a cell-
based assay format does not guarantee performance in vivo, 
failure in this assay is generally predictive of failure in the 
animal. In addition, the competition assays developed may 
subsequently be useful for demonstrating specifi city in ani-
mal experiments.
Animal care and use
All research animals must be handled according to protocols 
that comply with the animal care and use regulations of the 
country and institution where the research will be performed. 
In the United States, these regulations are described in a docu-
ment compiled by the National Institutes of Health Organiza-
tion for Lab Animal Welfare, available at  
http://grants.nih.gov/grants/olaw/GuideBook.pdf.
Considerations for tumor model selection
An ideal tumor model system exhibits minimal background 
interference. Although much of the autofl uorescence in the 
animal is ameliorated by imaging at NIR wavelengths, some 
anatomic regions inherently maintain higher fl uorescent sig-
nals. For example, natural fl uorescence from compounds in 
the animal’s diet accumulates and can be visualized in the ab-
dominal cavity. Organs involved in clearance of the dye, such 
as the liver and kidney, may also accumulate signal. Tumors 
arising in areas remote from these organs are detected with 
less ambiguity and higher sensitivity. In the case of subcuta-
neous xenografts, the placement of transplanted tissue in the 
fl ank, shoulder, or leg of the animal can minimize these inter-
fering factors.
The model system selected will depend on the aims of the 
study. Transgenic, chemically induced, and spontaneously 
arising mouse models that recapitulate many aspects of the 
genesis, progression, and clinical course of human cancers are 
available. The National Cancer Institute of the United States 
has organized a Cancer Models Database (caMOD) to facil-
itate identifi cation of appropriate models for cancer experi-
mental design (http://0-cancermodels.nci.nih.gov.library.unl.
edu:80/camod/login.do;jsessionid=D8B27DC9B409DA8CC3
7CE04150EBAABB).
Three strains of immunodefi cient mice are commonly used 
in tumorigenesis and metastasis research with human cell 
lines: nude, SCID, and Rag1. The nude mouse (athymic; nu/
nu) has a disruption in the Foxn1 gene, resulting in an absent 
or deteriorated thymus gland, diminished T cell numbers, and 
a severely impaired cellular immune system [56]. The resul-
tant hairless phenotype also makes the nude mouse ideal for 
optical imaging, since animal hair blocks and scatters light. 
Over time, these animals may regain partial cellular immune 
function so nude mice may not be the best host for longer-term 
studies of tumor biology. SCID (severe combined immunode-
fi ciency) mice lack both mature T and B lymphocytes [57] 
and are an effective alternative to nude mice in cases where 
the partial immune system of the nude mouse presents a prob-
lem. The Rag1 mouse also lacks T and B lymphocytes and is 
not able to undergo V(D)J recombination. Thus, it fails to pro-
duce T-cell receptors and immunoglobulin molecules for an-
tigen identifi cation [58], [59] and [60]. All three mouse mod-
els bear phenotypic and background strain characteristics that 
may impact a research project.
Immunocompromised mice require specifi c-pathogen-free 
handling to avoid introducing infections. Institutional training 
is obligatory and includes instruction in the use of infection 
barriers, sterilized food, water, and bedding, disinfected imag-
ing surfaces, gloved handling, and aseptic technique.
Figure 2. Binding activity of recombinant EGF from different com-
mercial sources. EGF from fi ve sources was conjugated to IRDye 
800CW at similar dye/protein ratios and each was evaluated for its 
ability to bind confl uent A431 monolayers by In-Cell Western as we 
have previously described [27]. 
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Reducing optical interference for tumor imaging
Chlorophyll, which is often present in animal chow, absorbs 
at 655 and 411 nm and fl uoresces at 673 nm, producing strong 
signal in the abdominal cavity. For optimal fl uorescent imag-
ing performance, purifi ed food formulations that do not con-
tain plant products may be used. Fasting of the animal prior to 
imaging has been used in some studies and requires prior ap-
proval from the institutional committee governing animal care.
The hairless phenotype of the nude mouse makes it an 
ideal choice for NIR optical imaging, but this model may not 
always be appropriate for the research objectives. Thus, hair 
removal in the imaging region may be important for opti-
mal signal detection. Animal hair interferes with imaging by 
blocking, absorbing, and scattering light. We evaluated this by 
implanting a tube containing IRDye 800CW in the chest cav-
ity of a deceased SCID mouse and imaging the animal before 
and after shaving. Following shaving, fl uorescent signal in-
creased by >50% (data not shown). An additional 12% signal 
was detected when the animal was treated with a depilatory 
cream (Nair, Church and Dwight Co., Inc.) presumably due to 
the removal of hair stubble.
Establishing tumors in the animal
For assays of tumorigenic and metastatic potential using cul-
tured human cells, cells or tissue may be implanted in animals 
subcutaneously, intravenously, intraperitonally, or orthotopi-
cally (i.e., prostate cells implanted in mouse prostate). These 
assays are called xenografts, since they involve transplanta-
tion of cells, tissue, or organs from one species to another.
Depending on the aggressiveness of the cell line, we have 
established subcutaneous xenografts in mice by injection of 
0.5–1 × 106 cells in ≈100 μL cell suspension. Tumors become 
palpable within 7–10 days. Orthotopic injections require 
fewer cells (we have used 1 × 105 cells) and reduced injection 
volume (10 μL), as the prostate is small. Tumors form in 2–3 
weeks and metastasize within ≈6 weeks [27] and [28].
Probe dosage and administration
Tumor type may dictate the optical imaging agent selected 
and its optimal parameters for use. For example, A431 epider-
moid carcinoma cells express EGFR at a much higher level 
than normal cells. However, HeLa ovarian carcinoma cells 
have low expression of EGFR. If IRDye 800CW EGF is used 
as an optical probe for both of these cell types, binding of the 
labeled ligand would be expected to vary dramatically.
An optimal dosage of the imaging agent will afford the 
best signal-to-background, clearance, and imaging results. Ex-
cessively high doses will clear poorly, while a low dose may 
not saturate tumor uptake. Figure 4 illustrates a dose response 
to increasing concentrations of an optical agent. Although 
background increases with the amount of probe administered, 
Figure 3. Binding specifi city of IRDye 800CW EGF for cultured PC3M-LN4 and 22Rv1 cells. Monolayer cells in 96-well microplates were in-
cubated with increasing concentrations of IRDye 800CW EGF (A) or unconjugated nonreactive IRDye 800CW (B) and normalized with TO-
PRO-3 staining. To demonstrate EGF receptor-targeting specifi city, cells were incubated with 70 nM IRDye 800CW EGF in the presence of in-
creasing concentrations of either C225 blocking antibody (C) or unlabeled EGF (D). The 800-nm signal, normalized to the 700-nm control, is 
plotted as the mean ± SD of three replicate wells [27]. This fi gure is reproduced with permission from the American Journal of Pathology. 
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the signal is also greater at the highest dose. The quantifi ed 
signal within the tumor, normalized to the mean background 
in several irrelevant surrounding regions, allowed us to deter-
mine that the optimal specifi c signal occurred at the two high-
est doses. 
The route of targeting agent administration can affect its 
specifi c uptake and nonspecifi c clearance. Intravenous injec-
tion via the tail vein or supraorbital cavity leads to rapid sys-
temic dispersion (Figure 5B). This method is appropriate for 
targeted contrast agents that bind a ubiquitous surface recep-
tor present at a greater concentration on tumor cells. Uptake 
by the tumor cells is within the time window of agent clear-
ance and potential background from prolonged exposure to 
the probe is minimized. Performance of an agent that func-
tions by incorporation into bone, however, may be enhanced 
by intraperitoneal injections, which prolong exposure through 
slower dispersion (Figure 5A). 
Evaluation of dye and optical agent clearance
Performing initial imaging time courses following injection 
of the chosen targeting agent will establish the optimal time 
point for sensitive tumor analysis. First, the time course anal-
ysis begins with the unconjugated fl uorochrome chosen for 
optical imaging, which should not be appreciably retained in 
the animal. An example of measurement of the clearance of 
IRDye 800CW is shown in Figure 6. Other dyes may have 
different clearance characteristics. Second, a time course of 
agent clearance from non-tumor-bearing control animals using 
the intended dose for tumor imaging will yield a blueprint for 
whole-body nonspecifi c background to assist interpretation of 
tumor images. Figure 7 shows the results of a clearance exper-
iment with IRDye 800CW EGF in a tumor-negative mouse. 
Finally, once it has been determined that the probe does 
not accumulate nonspecifi cally, the time course is repeated 
Figure 4. Dose response for an IRDye 800CW-conjugated optical imaging agent targeting tumors in nude mice. Animals were injected with 1× 
phosphate-buffered saline as a negative control (A), or with 2.5 nmol (B), 5.0 nmol (C), and 10 nmol (D) of a tumor-targeted IRDye 800CW 
conjugate. Images were acquired 24 h postinjection. 
Figure 5. Impact of administration site on optical imaging agent dispersion in mice. Images were acquired approximately 15 min following in-
traperitoneal (A) or intravenous (B) injection of equivalent amounts of an optical imaging agent into a nude mouse. 
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with tumor-bearing animals to determine the imaging time at 
which the signal-to-background is greatest in the tumor. For 
IRDye 800CW EGF, mice bearing PC3M-LN4 subcutaneous 
xenografts were imaged over a 3-day period. By 24 h, most 
of the initial fl uorescence was gone from the nontumor areas 
(Figure 8). However, signal-to-background continued to in-
crease beyond this time point. Optimizing the time of imaging 
maximizes sensitivity for challenging applications such as de-
tecting metastatic spread of a tumor. 
Confi rming probe specifi city in vivo
Clearance studies and optimization of timing will minimize 
nonspecifi c fl uorescence, but imaging artifacts may be misin-
terpreted nonetheless. For example, an apparent tumor detected 
in the liver upon targeting with an antibody probe that pooled in 
the liver should be confi rmed by a competition test. One method 
is to preinject tumor-bearing animals with an excess (for exam-
ple, 100-fold) of the unlabeled form of the optical agent. The 
labeled agent is injected shortly thereafter. Probe specifi city is 
refl ected as a decrease in the total fl uorescence signal in ani-
mals that were preinjected with the unlabeled agent. Specifi city 
of Cy5.5-labeled EGF was demonstrated in this way by Ke et 
al. [26]. Even if differential signal is not readily detected in in-
tact animals, imaging analysis of excised whole and sectioned 
tumors may reveal the competition.
We used this approach to assess specifi city of IRDye 
800CW EGF imaging in prostate tumors [27]. Mice bearing 
Figure 7. Time course for clearance of IRDye 800CW EGF from a non-tumor-bearing mouse. A SCID mouse was injected with 1 nmol of 
the EGF-conjugated optical agent intravenously and imaged at the indicated time points over a 24-h period. Analysis of the abdominal region 
showed that >90% of the fl uorescence disappeared in 24 h, and by 48 h (not shown) the probe had cleared completely. 
Figure 6. Clearance kinetics of unconjugated IRDye 800CW. A SCID mouse was injected with 1 nmol of IRDye 800CW intravenously and 
monitored over time for complete clearance of the dye. Imaging times postinjection are indicated on each individual image. Pseudocolored fl u-
orescence is superimposed on the white light image of the mouse to illustrate rapid dispersion of the dye followed by complete clearance. 
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either PC3M-LN4 subcutaneous or orthotopic tumors were 
injected with IRDye 800CW EGF; some animals were pre-
injected with C225 anti-EGFR monoclonal antibody. When 
we injected tumor-bearing animals with the probe and sub-
sequently performed fl uorescence imaging of tumor sections, 
IRDye 800CW EGF was clearly visible not only in the pri-
mary tumors but also in lymph nodes extracted from the ani-
mals (Figure 9). Tumor-bearing animals that were preinjected 
with C225 exhibited a 33–49% decrease in fl uorescent signal, 
indicating that binding of the labeled ligand was specifi c for 
EGFR. 
An alternative approach to demonstrating specifi c signal 
is to quantify targeting agent uptake by both tumor and non-
tumor tissue. For examining integrin-binding agents, Becker 
et al. [53] used an RGD peptide doubly labeled with 125I and 
an indocarbocyanine dye. Radioactive content of the tumor, 
Figure 8. Time course for accumulation of IRDye 800CW EGF in a subcutaneous tumor. Images of a nude mouse were collected prior to injec-
tion (A) or at 20 min (B), 24 h (C), 48 h (D), and 72 h (E) following intravenous injection of the animal with 1 nmol of IRDye 800CW EGF. 
Figure 9. Demonstration of specifi c tumor targeting in vivo for the IRDye 800CW EGF optical imaging agent. Tumors and lymph nodes 
were excised from animals bearing either subcutaneous (A) or orthotopic (B) prostate tumors, as indicated, injected intravenously with IRDye 
800CW EGF or preinjected with C225 anti-EGFR monoclonal antibody prior to dosing with IRDye 800CW EGF. The corresponding table 
presents IRDye 800CW EGF fl uorescence signal per area tissue for vehicle control, optical agent only, and C225 competition for each tumor 
type (subcutaneous and orthotopic) and lymph nodes from the orthotopic tumor model (C). 
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heart, liver, kidneys, and brain was quantifi ed following im-
aging of the tumor. Thus, the authors were able to express 
the uptake of the probe as the percentage of injected dose per 
gram of tissue. This approach may also be useful for charac-
terization of metabolic probes, for which high doses of unla-
beled competitor may be toxic.
Conclusions
Fluorochrome-labeled molecular probes are valuable tools for 
noninvasive longitudinal study of tumorigenesis and metasta-
sis, preclinical studies of the effects of therapeutic agents, and 
pharmacokinetic and pharmacodynamic studies of drug–target 
interactions. Because of this, these probes have signifi cant po-
tential for translation to human clinical use.
Several applications may expand the clinical utility of 
fl uorochrome-labeled probes. For example, accurate defi ni-
tion of tumor margins is crucial to the therapeutic outcome 
of many surgical oncology procedures. A multimodal imag-
ing agent consisting of a magnetic iron oxide nanoparticle and 
Cy5.5 has been used as a preoperative nuclear magnetic reso-
nance contrast agent and intraoperative optical probe to defi ne 
the tumor margins in a rat gliosarcoma model [61]. Similar 
intraoperative imaging technology is being developed in the 
laboratory of Frangioni [62]. These procedures would allow 
a surgeon to identify and locate the tumor mass by MRI and 
subsequently remove the tumor accurately with visual guid-
ance from an intraoperative near-infrared fl uorescent imager.
Photodynamic therapy is an application that has been used 
in oncology for over 2 decades [9]. A photosensitizing agent 
delivered to malignant tissue is exposed to light, generating 
cytotoxic singlet oxygen. The result is cell death through the 
induction of apoptosis, microvascular damage, and antitumor 
immune response. The major class of dyes used for this ap-
proach is phthalocyanines such as IRDye 700DX [8]. NIR 
dyes conjugated to antitumor therapeutics such as Erbitux 
(anti-EGFR monoclonal antibody) may have similar clinical 
appeal for simultaneous treatment and monitoring of antican-
cer therapy [63].
Imaging based on expression of luciferase or a fl uorescent 
protein such as GFP has facilitated examination of intracellu-
lar signaling events in vivo. Hybrid gene constructs in which 
either the luciferase or the GFP gene is placed under control 
of an inducible promoter responsive to a signaling pathway of 
interest have been used to directly assess the effects of antitu-
mor agents on the gene regulation in vivo. A similar reporter 
system that directly images β-galactosidase activity on a far-
red substrate has been recently reported [64]. This fl uorescent 
reporter system could provide a means for creating hybrid ex-
pression units to examine in vivo gene expression and regula-
tion of a number of important pathways in cancer.
NIR-based imaging instrument technologies designed for 
human clinical use are in various stages of development [62], 
[65] and [66]. Combined with new NIR-labeled biomark-
ers, these will expand the clinical options available for can-
cer management in the near future. Several excellent reviews 
describe the use of targeted markers in animal studies [7] and 
[67].
In this review we have discussed the basic validation of 
fl uorochrome-labeled molecular probes. Although near-infra-
red optical excitation sources provide deeper tissue penetra-
tion, they are not great enough to provide unlimited applica-
tion for human clinical use. Near-infrared imaging agents may 
be limited to accessible tissues such as breast tumors or to in-
traoperative applications, endoscopy, and photodynamic ther-
apy. However, these applications represent signifi cant benefi ts 
for research, diagnosis, and treatment. Continued technologi-
cal innovation in imaging instrumentation, biomarker discov-
ery, and labeling chemistries will foster the clinical use of fl u-
orescent optical imaging. 
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